Print
Email
Print Edition Stories
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Pervasis Therapeutics Inc. said Tuesday that the U.S. Food and Drug Administration has cleared the way for the Cambridge-based company to begin its Phase 3 trial of its drug candidate to treat symptoms linked to end-stage renal disease.
The drug target, called Vascugel, will be tested in approximately 390 patients with end-stage renal disease. Pervasis plans to start the drug trial this year, and, if the results are positive, to submit the drug for market approval.
Pervasis recently published positive trial results for Vascugel in the December issue of the Journal of Vascular Surgery.
Pervasis develops technologies to identify drug targets for vascular diseases, inflammatory diseases and orthopedic diseases.
Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. The company raised $10 million in September as part of a third round of funding.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
